Tivicay (dolutegravir) is an integrase inhibitor approved by the U.S. Food and Drug Administration (FDA), and the regulatory authorities in Canada, Chile, Australia and Europe, for the treatment of HIV-1.

Elsewhere in the world dolutegravir is subject to evaluation of the benefits and risks by respective regulatory authorities before it can be approved and made available on prescription.

For more information for healthcare professionals, please visit www.tivicay.com.

Please refer to local prescribing information for more details.



United States


Other Resources